Literature DB >> 8223840

The pharmacokinetics of clonidine in high dosage.

J Fauler1, L Verner.   

Abstract

We have evaluated the pharmacokinetics of high doses of clonidine, as used in the prophylactic treatment of alcohol withdrawal syndrome, in 11 alcohol-dependent patients undergoing surgery for oesophagogastrectomy. Clonidine was given in a bolus of 150 micrograms followed by a continuous infusion. After a mean period of treatment of 9.2 (range 3 to 26) days and a mean dose of 0.72 (range 0.29 to 2.37) mg per day of clonidine the mean terminal half-life was 15.8 (range 9.9 to 23) h (n = 7). In order to compare initial and terminal half-lives of clonidine intraindividually, four patients were given a bolus of 150 micrograms followed 24 h later by a continuous infusion. The pharmacokinetics of clonidine were described by two exponentials, with a distribution half-life of 1.2 h and a terminal half-life of 14.6 h. After a mean period of 8.3 (range 2 to 15) days and a mean dose of 0.62 (range 0.15 to 1.82) mg per day the terminal half-life in these four patients was 15.6 (range 14.0 to 17.9) h. The relation between dosage and plasma concentration was linear.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223840     DOI: 10.1007/bf00315500

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Clonidine in alcohol withdrawal.

Authors:  S E Björkqvist
Journal:  Acta Psychiatr Scand       Date:  1975-10       Impact factor: 6.392

2.  [Clonidine supplemented analgesia and sedation in prevention of postoperative delirium].

Authors:  L Verner; M Hartmann; W Seitz
Journal:  Anasth Intensivther Notfallmed       Date:  1990-08

3.  Pharmacokinetics of transdermally delivered clonidine.

Authors:  T R MacGregor; K M Matzek; J J Keirns; R G van Wayjen; A van den Ende; R G van Tol
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

4.  Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomized, controlled clinical trial.

Authors:  G R Baumgartner; R C Rowen
Journal:  South Med J       Date:  1991-03       Impact factor: 0.954

5.  Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome.

Authors:  G R Baumgartner; R C Rowen
Journal:  Arch Intern Med       Date:  1987-07

6.  Pharmacokinetics and antihypertensive effects of low dose clonidine during chronic therapy.

Authors:  S N Anavekar; L G Howes; B Jarrott; M Syrjanen; E L Conway; W J Louis
Journal:  J Clin Pharmacol       Date:  1989-04       Impact factor: 3.126

7.  Efficacy of clonidine in treatment of alcohol withdrawal state.

Authors:  A J Wilkins; W J Jenkins; J A Steiner
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

Review 8.  Clinical pharmacokinetics of clonidine.

Authors:  D T Lowenthal; K M Matzek; T R MacGregor
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

9.  Plasma clonidine concentration and pharmacologic effect.

Authors:  M J Hogan; J D Wallin; L C Chu
Journal:  Clin Pharmacol Ther       Date:  1981-12       Impact factor: 6.875

  9 in total
  5 in total

Review 1.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 2.  Is clonidine an effective smoking cessation therapy?

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

3.  Differential central NOS-NO signaling underlies clonidine exacerbation of ethanol-evoked behavioral impairment.

Authors:  Tara S Bender; Abdel A Abdel-Rahman
Journal:  Alcohol Clin Exp Res       Date:  2009-12-17       Impact factor: 3.455

4.  Alpha 2A-adrenergic receptor signaling underlies synergistic enhancement of ethanol-induced behavioral impairment by clonidine.

Authors:  Tara Summer Bender; Abdel A Abdel-Rahman
Journal:  Alcohol Clin Exp Res       Date:  2008-12-13       Impact factor: 3.455

5.  Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics.

Authors:  Michael E Cloesmeijer; Huub L A van den Oever; Ron A A Mathôt; Marieke Zeeman; Arriette Kruisdijk-Gerritsen; Carmen M A Bles; Polina Nassikovker; Arthur R de Meijer; Fred L van Steveninck; Maurits E L Arbouw
Journal:  Br J Clin Pharmacol       Date:  2020-03-29       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.